Literature DB >> 16969854

A heterozygous effect for PINK1 mutations in Parkinson's disease?

Patrick M Abou-Sleiman1, Miratul M K Muqit, Neil Q McDonald, Yan Xiang Yang, Sonia Gandhi, Daniel G Healy, Kirsten Harvey, Robert J Harvey, Emma Deas, Kailash Bhatia, Niall Quinn, Andrew Lees, David S Latchman, Nicholas W Wood.   

Abstract

OBJECTIVE: To investigate the significance of PINK1 mutations in sporadic Parkinson's disease (PD).
METHODS: We determined the frequency of PINK1 mutations by direct sequencing in a large series of PD patients with apparently sporadic disease (n = 768).
RESULTS: Twelve heterozygous mutations were identified, nine in PD patients and three in control subjects.
INTERPRETATION: Given the difficulty in interpreting the pathogenic significance of the heterozygous mutations that have already been reported in parkin and DJ-1, we first determined the frequency of heterozygous PINK1 mutations in the general population by sequencing a large number of control subjects (n = 768), then subsequently assessed their functional significance by examining their effects on stress-induced alterations to the mitochondrial membrane potential (DeltaPsim). We demonstrate an enrichment of heterozygous mutations in sporadic PD patients compared with matched control subjects (1.2% in PD vs 0.4% in control subjects). Furthermore, we show that they adversely affect DeltaPsim in a similar way to the familial G309D mutation. Although it remains difficult to conclusively demonstrate the pathogenicity of heterozygous mutations, the results of this study and the previously reported subclinical nigrostriatal dysfunction in carriers of heterozygous PINK1 mutations suggest the possibility that these heterozygous mutations are a significant risk factor in the development of later onset PD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16969854     DOI: 10.1002/ana.20960

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  50 in total

1.  Co-occurrence of affective and schizophrenia spectrum disorders with PINK1 mutations.

Authors:  Susanne Steinlechner; Jessica Stahlberg; Birgit Völkel; Ana Djarmati; Johann Hagenah; Anja Hiller; Katja Hedrich; Inke König; Christine Klein; Rebekka Lencer
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-01-03       Impact factor: 10.154

2.  Physiology versus pathology in Parkinson's disease.

Authors:  Ken Nakamura; Robert H Edwards
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-10       Impact factor: 11.205

3.  PINK1 and its familial Parkinson's disease-associated mutation regulate brain vascular endothelial inflammation.

Authors:  Wang Yunfu; Liu Guangjian; Zhong Ping; Sun Yanpeng; Fang Xiaoxia; Hu Wei; Yuan Jiang; Hu Jingquan; Wang Songlin; Zhang Hongyan; Liu Yong; Chen Shi
Journal:  J Mol Neurosci       Date:  2014-01-03       Impact factor: 3.444

4.  Accurate zygote-specific discrimination of single-nucleotide polymorphisms using microfluidic electrochemical DNA melting curves.

Authors:  Allen H J Yang; Kuangwen Hsieh; Adriana S Patterson; B Scott Ferguson; Michael Eisenstein; Kevin W Plaxco; H Tom Soh
Journal:  Angew Chem Int Ed Engl       Date:  2014-02-12       Impact factor: 15.336

5.  Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease.

Authors:  L N Clark; B M Ross; Y Wang; H Mejia-Santana; J Harris; E D Louis; L J Cote; H Andrews; S Fahn; C Waters; B Ford; S Frucht; R Ottman; K Marder
Journal:  Neurology       Date:  2007-09-18       Impact factor: 9.910

6.  Comprehensive assessment of PINK1 variants in Parkinson's disease.

Authors:  Lynne Krohn; Francis P Grenn; Mary B Makarious; Jonggeol Jeffrey Kim; Sara Bandres-Ciga; Dorien A Roosen; Ziv Gan-Or; Mike A Nalls; Andrew B Singleton; Cornelis Blauwendraat
Journal:  Neurobiol Aging       Date:  2020-03-10       Impact factor: 4.673

Review 7.  Autophagy and the degradation of mitochondria.

Authors:  Scott J Goldman; Robert Taylor; Yong Zhang; Shengkan Jin
Journal:  Mitochondrion       Date:  2010-01-18       Impact factor: 4.160

8.  Clinical and molecular characterisation of a Parkinson family with a novel PINK1 mutation.

Authors:  Jügen Prestel; Klaus Gempel; Till-Karsten Hauser; Katherine Schweitzer; Holger Prokisch; Uwe Ahting; Dirk Freudenstein; Eva Bueltmann; Thomas Naegele; Daniela Berg; Thomas Klopstock; Thomas Gasser
Journal:  J Neurol       Date:  2008-02-21       Impact factor: 4.849

Review 9.  Mitochondrial quality control and neurological disease: an emerging connection.

Authors:  Inês Pimenta de Castro; L Miguel Martins; Roberta Tufi
Journal:  Expert Rev Mol Med       Date:  2010-04-19       Impact factor: 5.600

10.  Targeting the progression of Parkinson's disease.

Authors:  J L George; S Mok; D Moses; S Wilkins; A I Bush; R A Cherny; D I Finkelstein
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.